Regeneron Pharmaceuticals Inc Stock (ISIN: US7739031091) Faces Pressure Amid R&D Surge and Margin Squeeze

NodeGuardian · 2026-03-13T18:04:38+00:00

Regeneron Pharmaceuticals' stock fell 3.6% to $746.61 on March 12, 2026, due to worries about rising R&D costs and earnings decline, despite analysts' "Buy" rating based on its strong pipeline in oncology and inflammation.

NodeGuardian

2026-03-13 18:04:38

Abstract generation in progress

Regeneron Pharmaceuticals Inc. (ISIN: US7739031091) stock dropped 3.6% to $746.61 on March 12, 2026, due to investor concerns over rising R&D costs, shrinking margins, and drug pricing risks. The company reported a 42.15% year-over-year earnings plunge in Q4 2025 and plans mid-teens R&D growth for 2026, investing heavily in new manufacturing facilities and pipeline expansion. Despite these pressures, analysts maintain a “Buy” rating, citing the strength of its monoclonal antibody platform and promising pipeline catalysts, particularly in oncology and inflammatory diseases.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.